Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Non-small Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 1,580 (planned)
- Started
- Jan 7, 2025
- Main results expected
- Jan 2029
- Fully finished
- Dec 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs
Measured over: From the first dose of the investigational medicinal product (IMP) to the 90-day Follow-Up Visit
Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs)
Measured over: From the first dose of IMP to the 90-day Follow-Up Visit
Phase 2 - Objective response rate (ORR)
Measured over: Up to approximately 2 years
Phase 2 - Best percentage change from baseline in tumor size
Measured over: Up to approximately 2 years
Phase 3 - Progression free survival (PFS) assessed by BICR
Measured over: Up to approximately 5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06712316 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC